HealthDay | Anti-CD20 Antibody + Chemo Benefits CLL With Comorbidity Monthly Prescribing Reference (HealthDay News) – For patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associated with improved outcomes, according to ... New Drug Combo Might Help Older, Sicker Patients With Leukemia |
